🕒 Last update: loading…

Stock Genprex, Inc. GNPX

Genprex, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -70.91%

Price change 2019 → 2020: 1196.88%

Price change 2020 → 2021: -68.43%

Price change 2021 → 2022: 10.69%

Price change 2022 → 2023: -84.14%

Price change 2023 → 2024: -90.74%

Price change 2024 → 2025: -95.89%

Price change 2025 → 2026: 52.00%

Price change 2026 (year to date): 48.60%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.02

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 84.49% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Genprex, Inc.–0.00–🔒
WORK Medical Technology Group Ltd.–0.35−28.4 %–
Spineway S.A.–0.07+9.3 %–
CompuMed, Inc.–0.23+10.2 %–
SpineGuard S.A.–0.27+1.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Genprex, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-16.50
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.96 x
low debt
Fiscal year20212022202320242025
Cash and investmentsn/a21.0 m6.7 m1.6 m7.8 m
Total Debt00000
Net Debtn/a-21.0 m-6.7 m-1.6 m-7.8 m
Equityn/a22.3 m7.4 m1.6 m8.0 m
Total assetsn/a25.1 m10.7 m4.1 m10.2 m
Operating cash flow-14.3 m-17.8 m-24.7 m-17.1 m-15.3 m
Investments (capex)83,79659,73571,38301
Free cash-flow-14.4 m-17.8 m-24.8 m-17.1 m-15.3 m
Share buybacks00000
Dividends paid000n/a0

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.01 x
Price / book value0.07 x
Return on Equity (ROE)-163.1 %
Return on Invested Capital (ROIC)-107.1 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio6.77 x
Interest coverage-34.78 x
Free cash-flow yield-1,394.6 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Valuation and competitors

Genprex, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Genprex, Inc.1.0 mn/a0.0 %
InMed Pharmaceuticals Inc. INM8.5 mn/a-165.1 %
Liminatus Pharma, Inc. Class A Common Stock LIMN3.4 mn/a0.0 %
Biodexa Pharmaceuticals Plc BDRX231,248n/a0.0 %
Jaguar Health, Inc. JAGX939,338n/a-464.2 %
GRI Bio, Inc. GRI4.1 mn/a0.0 %
BioVie Inc. BIVI11.3 mn/a0.0 %
CNS Pharmaceuticals, Inc. CNSP5.7 mn/a0.0 %
Theriva Biologics, Inc. TOVX7.6 mn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Genprex, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
13/11/2026-5.30-6,160.00n/a
30/03/2026-25.30-286.00n/a
14/11/2025-109.89-275.00n/a
08/08/2025-187.00-15.62n/a
12/05/2025-285.71-55.88n/a
01/04/2025-462.00-18.04n/a

Stock splits

DateOperation
16/07/2026reverse split: 1 share for 22
21/10/2025reverse split: 1 share for 50
02/02/2024reverse split: 1 share for 40

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Genprex, Inc.

Free float
95.1 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 29/03/2018
ISIN code
US3724463027
Workforce
15
full-time employees
Chief executive
Ryan M. Confer

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Genprex, Inc.

What is the Genprex, Inc. share price?

Latest recorded price: 2.08 USD on 13/11/2026, for a market cap of 1.1 m USD.

Is Genprex, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US3724463027).

How many employees does Genprex, Inc. have?

15 full-time employees according to the latest published profile.

Who runs Genprex, Inc.?

Ryan M. Confer is the company's chief executive.

07

Similar stocks